IL182662A - Antibody for Glyphican Antigen 3 and Methods for Preparation - Google Patents
Antibody for Glyphican Antigen 3 and Methods for PreparationInfo
- Publication number
- IL182662A IL182662A IL182662A IL18266207A IL182662A IL 182662 A IL182662 A IL 182662A IL 182662 A IL182662 A IL 182662A IL 18266207 A IL18266207 A IL 18266207A IL 182662 A IL182662 A IL 182662A
- Authority
- IL
- Israel
- Prior art keywords
- amino acid
- seq
- set forth
- acid sequence
- sequence set
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 description 74
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 6
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 6
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004311356 | 2004-10-26 | ||
| PCT/JP2005/020057 WO2006046751A1 (ja) | 2004-10-26 | 2005-10-26 | 糖鎖改変抗グリピカン３抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL182662A0 IL182662A0 (en) | 2007-09-20 |
| IL182662A true IL182662A (en) | 2014-09-30 |
Family
ID=36227980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL182662A IL182662A (en) | 2004-10-26 | 2007-04-19 | Antibody for Glyphican Antigen 3 and Methods for Preparation |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7867734B2 (ko) |
| EP (1) | EP1816140A4 (ko) |
| JP (1) | JP4794457B2 (ko) |
| KR (1) | KR101296931B1 (ko) |
| CN (1) | CN101068836B (ko) |
| AU (1) | AU2005297772B2 (ko) |
| BR (1) | BRPI0518279A2 (ko) |
| CA (1) | CA2585196C (ko) |
| CR (1) | CR9151A (ko) |
| HK (1) | HK1110335A1 (ko) |
| IL (1) | IL182662A (ko) |
| MA (1) | MA29025B1 (ko) |
| MX (1) | MX2007004593A (ko) |
| NO (1) | NO20072366L (ko) |
| NZ (1) | NZ554940A (ko) |
| RU (1) | RU2451030C2 (ko) |
| TW (1) | TWI468514B (ko) |
| UA (1) | UA93488C2 (ko) |
| WO (1) | WO2006046751A1 (ko) |
| ZA (1) | ZA200703888B (ko) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
| ES2348008T3 (es) * | 2003-06-18 | 2010-11-26 | Chugai Seiyaku Kabushiki Kaisha | Transportador de fucosa. |
| BRPI0506125B8 (pt) | 2004-07-09 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | anticorpo anti - glipicano 3, seu método de produção, polinucleotídeo, vetor e inibidor do crescimento de células |
| SI1800693T1 (sl) | 2004-08-24 | 2013-11-29 | Chugai Seiyaku Kabushiki Kaisha | Adjuvantna terapija z uporabo protitelesa proti glipikanu 3 |
| CA2585196C (en) * | 2004-10-26 | 2015-01-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| HUE028737T2 (en) | 2007-07-17 | 2017-01-30 | Squibb & Sons Llc | Monoclonal antibodies to GLYPICAN-3 |
| PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
| MX2010003158A (es) * | 2007-09-28 | 2010-04-14 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-glipicano-3 que tiene cinetica mejorada en plasma. |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
| US8589541B2 (en) | 2009-01-28 | 2013-11-19 | Headwater Partners I Llc | Device-assisted services for protecting network capacity |
| US8270952B2 (en) | 2009-01-28 | 2012-09-18 | Headwater Partners I Llc | Open development system for access service providers |
| US11985155B2 (en) | 2009-01-28 | 2024-05-14 | Headwater Research Llc | Communications device with secure data path processing agents |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
| TWI693073B (zh) * | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑 |
| WO2015109265A1 (en) * | 2014-01-16 | 2015-07-23 | Calysta, Inc. | Microorganisms for the enhanced production of amino acids and related methods |
| CN113933504A (zh) | 2014-05-08 | 2022-01-14 | 中外制药株式会社 | 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| EP3318879B1 (en) | 2015-07-01 | 2020-10-21 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective |
| CA2994751A1 (en) * | 2015-08-03 | 2017-02-09 | Carsgen Therapeutics, Ltd | Antibody against glypican-3 and application thereof |
| KR101796688B1 (ko) | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
| BR112018015259A2 (pt) | 2016-01-27 | 2018-12-18 | Medimmune Llc | métodos para preparação de anticorpos com um padrão de glicosilação definido |
| CN109153719B (zh) | 2016-03-15 | 2022-12-30 | 中外制药株式会社 | 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法 |
| WO2018019772A1 (en) | 2016-07-26 | 2018-02-01 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
| EP3502250B1 (en) | 2016-08-22 | 2024-04-24 | Chugai Seiyaku Kabushiki Kaisha | Gene-modified rodent expressing human gpc3 polypeptide |
| CN106591371A (zh) * | 2016-11-25 | 2017-04-26 | 哈尔滨百伊生生物科技有限公司 | Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用 |
| US20200216542A1 (en) | 2017-09-20 | 2020-07-09 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
| SG11202103234RA (en) | 2018-10-01 | 2021-04-29 | Adicet Bio Inc | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
| WO2020131697A2 (en) | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
| CA3140914A1 (en) | 2019-05-24 | 2020-12-03 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-csf1r antibodies, il10 fusion proteins, and uses thereof |
| EP4023230A4 (en) | 2019-06-05 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | ANTIBODY CLEAVAGE SITE BINDING MOLECULE |
| WO2022171100A1 (zh) * | 2021-02-10 | 2022-08-18 | 江苏先声药业有限公司 | Gpc3人源化抗体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0242355A (ja) | 1988-08-02 | 1990-02-13 | Hitachi Constr Mach Co Ltd | 超音波検査装置 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JPH04336051A (ja) | 1991-05-10 | 1992-11-24 | Toshiba Corp | 超音波診断装置 |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| SK110099A3 (en) * | 1997-02-12 | 2000-08-14 | Chugai Pharmaceutical Co Ltd | Remedies for lymphocytic tumors, an antibody, chimeric antibody and modified antibody |
| US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| WO1999018212A1 (fr) * | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain naturel |
| JPH11118775A (ja) | 1997-10-09 | 1999-04-30 | Canon Inc | 超音波検査装置 |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| JP3606132B2 (ja) | 1999-10-14 | 2005-01-05 | Ｊｆｅエンジニアリング株式会社 | 超音波探傷方法およびその装置 |
| JP2002048867A (ja) | 2000-08-07 | 2002-02-15 | Mitsubishi Heavy Ind Ltd | 音響探査装置 |
| DE60128817T2 (de) | 2000-09-12 | 2008-02-07 | Union Carbide Chemicals & Plastics Technology Corp., Danbury | Polymerische mischungen enthaltend ethylenoxid-copolymere |
| EP2314686B2 (en) * | 2000-10-06 | 2023-06-21 | Kyowa Kirin Co., Ltd. | Cells producing antibody compositions |
| JP4336051B2 (ja) | 2001-01-31 | 2009-09-30 | 株式会社エヌ・ティ・ティ・ドコモ | 無線通信端末、発呼制限方法及びプログラム |
| US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
| KR100877176B1 (ko) | 2001-06-22 | 2009-01-07 | 츄가이 세이야꾸 가부시키가이샤 | 항글리피칸 3항체를 포함하는 세포증식 억제제 |
| EP1423510A4 (en) * | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
| JP3961359B2 (ja) | 2002-07-18 | 2007-08-22 | 株式会社東芝 | 超音波画像化装置 |
| JP4087098B2 (ja) | 2001-11-14 | 2008-05-14 | 株式会社東芝 | 超音波検査装置 |
| KR100572236B1 (ko) | 2001-11-14 | 2006-04-19 | 가부시끼가이샤 도시바 | 초음파 검사 장치, 초음파 트랜스듀서 및 초음파 화상화 장치 |
| US20050171339A1 (en) | 2001-12-28 | 2005-08-04 | Izumi Sugo | Method of stabilizing protein |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20040259150A1 (en) * | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| ES2324029T3 (es) | 2002-05-23 | 2009-07-29 | Sunnybrook And Women's College Health Sciences Centre | Diagnostico de carcinoma hepatocelular. |
| WO2004018667A1 (ja) | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ペプチド及びこれを含む医薬 |
| AU2002330482A1 (en) | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
| AU2002328429A1 (en) | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
| AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| EP1671645A4 (en) | 2003-09-04 | 2007-07-25 | Chugai Pharmaceutical Co Ltd | REMEDIES AND MEDIUM FOR DETECTING GALLENGIFT CANCER |
| ITBO20040008U1 (it) | 2004-02-03 | 2004-05-03 | Tonazzi S R L | Macchina per il riempimento e la chiusura di tubetti |
| BRPI0506125B8 (pt) | 2004-07-09 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | anticorpo anti - glipicano 3, seu método de produção, polinucleotídeo, vetor e inibidor do crescimento de células |
| DE602005024147D1 (de) * | 2004-08-08 | 2010-11-25 | Eli Khayat | Pharmazeutische zusammensetzungen zur linderung von übermässig hohen zuckerspiegeln bei diabetikern |
| AU2005277567A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
| SI1800693T1 (sl) | 2004-08-24 | 2013-11-29 | Chugai Seiyaku Kabushiki Kaisha | Adjuvantna terapija z uporabo protitelesa proti glipikanu 3 |
| CA2585196C (en) * | 2004-10-26 | 2015-01-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
| JPWO2006067847A1 (ja) * | 2004-12-22 | 2008-06-12 | 中外製薬株式会社 | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| PL2202245T3 (pl) * | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
| EP2270509B1 (en) * | 2008-03-17 | 2014-01-15 | University of Miyazaki | Method for detection of liver cancer cell using anti-glypican-3 antibody |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
-
2005
- 2005-10-26 CA CA2585196A patent/CA2585196C/en not_active Expired - Fee Related
- 2005-10-26 RU RU2007119579/10A patent/RU2451030C2/ru not_active IP Right Cessation
- 2005-10-26 JP JP2006542382A patent/JP4794457B2/ja not_active Expired - Fee Related
- 2005-10-26 BR BRPI0518279-4A patent/BRPI0518279A2/pt not_active IP Right Cessation
- 2005-10-26 MX MX2007004593A patent/MX2007004593A/es active IP Right Grant
- 2005-10-26 WO PCT/JP2005/020057 patent/WO2006046751A1/ja active Application Filing
- 2005-10-26 KR KR1020077011403A patent/KR101296931B1/ko not_active IP Right Cessation
- 2005-10-26 CN CN2005800368760A patent/CN101068836B/zh not_active Expired - Fee Related
- 2005-10-26 TW TW94137496A patent/TWI468514B/zh not_active IP Right Cessation
- 2005-10-26 AU AU2005297772A patent/AU2005297772B2/en not_active Ceased
- 2005-10-26 UA UAA200705812A patent/UA93488C2/uk unknown
- 2005-10-26 NZ NZ554940A patent/NZ554940A/en not_active IP Right Cessation
- 2005-10-26 EP EP05800031A patent/EP1816140A4/en not_active Ceased
- 2005-10-26 US US11/577,944 patent/US7867734B2/en not_active Expired - Fee Related
-
2007
- 2007-04-19 IL IL182662A patent/IL182662A/en not_active IP Right Cessation
- 2007-05-09 NO NO20072366A patent/NO20072366L/no not_active Application Discontinuation
- 2007-05-14 ZA ZA200703888A patent/ZA200703888B/xx unknown
- 2007-05-17 MA MA29912A patent/MA29025B1/fr unknown
- 2007-05-25 CR CR9151A patent/CR9151A/es not_active Application Discontinuation
-
2008
- 2008-04-23 HK HK08104536.5A patent/HK1110335A1/xx not_active IP Right Cessation
-
2010
- 2010-08-09 US US12/852,950 patent/US20110033452A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007004593A (es) | 2007-06-22 |
| UA93488C2 (uk) | 2011-02-25 |
| US7867734B2 (en) | 2011-01-11 |
| CA2585196C (en) | 2015-01-06 |
| US20110033452A1 (en) | 2011-02-10 |
| JPWO2006046751A1 (ja) | 2008-05-22 |
| EP1816140A1 (en) | 2007-08-08 |
| KR101296931B1 (ko) | 2013-08-14 |
| HK1110335A1 (en) | 2008-07-11 |
| CN101068836A (zh) | 2007-11-07 |
| NZ554940A (en) | 2010-04-30 |
| RU2451030C2 (ru) | 2012-05-20 |
| TW200621980A (en) | 2006-07-01 |
| ZA200703888B (en) | 2009-11-25 |
| AU2005297772A1 (en) | 2006-05-04 |
| TWI468514B (zh) | 2015-01-11 |
| US20080124330A1 (en) | 2008-05-29 |
| NO20072366L (no) | 2007-06-21 |
| EP1816140A4 (en) | 2009-09-02 |
| CN101068836B (zh) | 2013-08-14 |
| RU2007119579A (ru) | 2008-12-10 |
| AU2005297772B2 (en) | 2011-06-23 |
| JP4794457B2 (ja) | 2011-10-19 |
| WO2006046751A1 (ja) | 2006-05-04 |
| KR20070070222A (ko) | 2007-07-03 |
| CA2585196A1 (en) | 2006-05-04 |
| CR9151A (es) | 2008-03-18 |
| MA29025B1 (fr) | 2007-11-01 |
| IL182662A0 (en) | 2007-09-20 |
| BRPI0518279A2 (pt) | 2008-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL182662A (en) | Antibody for Glyphican Antigen 3 and Methods for Preparation | |
| WO2006068953A3 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| RU2006104842A (ru) | Антитело против глипикана 3 | |
| WO2007070432A3 (en) | Binding proteins specific for insulin-like growth factors and uses thereof | |
| NZ581418A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
| WO2006103100A3 (en) | Antibodies against ccr5 and uses thereof | |
| WO2006081139A3 (en) | Antibodies against interleukin-1 beta | |
| EP2686349B1 (en) | Antibody screening methods | |
| NZ597466A (en) | Recombinant anti-epidermal growth factor receptor antibody compositions | |
| WO2006130458A3 (en) | Antibodies directed to cd20 and uses thereof | |
| WO2005118635A3 (en) | Anti-cd3 antibodies and methods of use thereof | |
| SG156547A1 (en) | Human monoclonal antibodies to ctla-4 | |
| CA2525139A1 (en) | Cd20 binding molecules | |
| HRP20130922T1 (hr) | U potpunosti humana protutijela protiv humanog 4-1bb (cd137) | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| WO2007120693A3 (en) | Targeted binding agents directed to upar and uses thereof | |
| WO2004050683A3 (en) | Antibodies directed to tumor necrosis factor and uses thereof | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2006039258A3 (en) | Human antibodies against parathyroid hormone | |
| WO2005016111A3 (en) | Antibodies directed to parathyroid hormone (PTH) and uses thereof | |
| WO2008112004A3 (en) | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF | |
| NZ592151A (en) | Anti-igf antibodies | |
| WO2004050850A3 (en) | Antibodies directed to phospholipase a2 and uses thereof | |
| CA2818635C (en) | Antibodies selective for cells presenting erbb2 at high density | |
| WO2006104978A3 (en) | Antibodies against the tenascin major antigens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |